How to Buy Allogene Therapeutics Stock
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
Allogene Therapeutics stock last closed at $2.70, up 3.45% from the previous day, and has decreased 10% in one year. It has overperformed other stocks in the Biotechnology industry by 0 percentage points. Allogene Therapeutics stock is currently +34.33% from its 52-week low of $2.01, and -53.25% from its 52-week high of $5.78.
There are currently 209.11M shares of ALLO outstanding. The market cap of ALLO is $564.60M. In the last 24 hours, 1.38M ALLO shares were traded.
How to Buy Allogene Therapeutics Stock
Wondering how to invest in Allogene Therapeutics stock? Here's how.
- Decide where to buy Allogene Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Allogene Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your payment method and add your details.
- Analyze Allogene Therapeutics stock: The Allogene Therapeutics ticker symbol is ALLO. Is Allogene Therapeutics stock a good investment? Should you buy shares of ALLO? How do ALLO's underlying business fundamentals look? Do top analysts think Allogene Therapeutics is a good buy? Why has ALLO's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if ALLO is a good stock to buy).
- Execute your ALLO trade: Decide if you will purchase ALLO shares at the current market price or use a limit order to purchase ALLO stock at a specific price.
- Track your investment in ALLO: Create a watchlist to watch your new investment in Allogene Therapeutics stock.
Step 1: Decide where to buy Allogene Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy ALLO shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro now.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal details so you are able to buy ALLO stock today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start your new trading account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have filled out your info on mobile trading apps, you can securely and quickly fund your account:
Watch this video walkthrough to see the process of depositing money into your new investment account.
Step 4: Analyze Allogene Therapeutics stock
Once you have chosen the best place to buy Allogene Therapeutics stock, it's very important to research their stock prior to buying, so you can wrap your head around the risk and upside.
Allogene Therapeutics Metrics
ALLO Fundamentals
WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on ALLO's stock page.
How is ALLO stock valued?
You can use many financial metrics, analyses, models, and charts to gauge ALLO's intrinsic value.
Using relative valuations metrics:
- ALLO may be undervalued based on its P/B ratio of 1.1x, relative to Biotechnology industry P/B ratio of 5.96x
You can do additional valuation analysis on ALLO's stock here.
Is ALLO a healthy company?
Passed Health Checks:
- There are more short-term assets than short-term liabilities on the ALLO balance sheet.
- ALLO has cash burn of 228925000. It has sufficient cash and short-term investments to cover this for at least one year.
- ALLO has a low debt to equity ratio of 0.26.
- ALLO has $454.92M in cash and short term investments. This is sufficient to cover its annual cash burn of $228.93M.
- There are more short-term assets than long-term liabilities on the ALLO balance sheet.
Failed Health Checks:
- Total ALLO debt is higher than 5 years ago, relative to shareholder equity.
- ALLO profit margin has gone down from -598,323% to -1,342,523.8% in the past year.
Do analysts think it's a good time to buy Allogene Therapeutics stock
Out of 8 Wall Street analysts who monitor ALLO, the consensus analyst rating on ALLO is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Most Recent ALLO Analyst Upgrades/Downgrades
Biren Amin, a bottom 8% analyst from Piper Sandler initiates coverage on ALLO with a strong buy rating and announces their ALLO price target of $11.00, on May 31, 2024.
Mark Breidenbach, a top 12% analyst from Oppenheimer maintains ALLO with a buy rating and lowers their ALLO price target from $14.00 to $13.00, on May 21, 2024.
Benjamin Burnett, a bottom 9% analyst from Stifel Nicolaus maintains ALLO with a hold rating and raises their ALLO price target from $4.40 to $4.60, on May 14, 2024.
You can dig deeper into what analysts are projecting on the Allogene Therapeutics stock forecast page.
ALLO Technicals
Is ALLO Growing Revenue?
Last year, ALLO revenue was $21.00k. Over the past 3 year, ALLO's revenue has gone up by -99.98% per year. This was slower than the Biotechnology industry average of 61.66%.
Dive into ALLO's earnings and revenue performance here.
What are ALLO insiders up to?
In the past year, executives and large shareholders at ALLO have bought more shares than they have sold.
Earl Martin Douglas, SVP General Counsel of ALLO, was the latest ALLO insider to sell. They sold $78,843.35 worth of ALLO stock on Aug 21, 2024.
Research more about who owns ALLO shares here.
Does ALLO provide a stable income stream?
No, Allogene Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about ALLO
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your ALLO trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, use a limit order.
Press the Open button and your broker will place the order.
If you require more assistance buying stocks on eToro, watch the helpful video below:
Step 6: Track your investment in ALLO
Now that you own some ALLO stock, you'll want to keep up with your new stock purchase.
Start a watchlist to track your ALLO stock.
ALLO Feed
How to Buy Stock in Allogene Therapeutics
To summarize, here are the 6 steps for buying Allogene Therapeutics stock:
- Decide where to buy Allogene Therapeutics stock
- Sign up for a brokerage account
- Fund your brokerage account
- Analyze Allogene Therapeutics stock
- Execute your ALLO trade
- Track your investment in ALLO
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Allogene Therapeutics, create a watchlist today.
Other Stock Buying Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.